These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16305996)

  • 1. Preparation and evaluation of floating risedronate sodium-Gelucire 43/01 formulations.
    Chauhan B; Shimpi S; Mahadik KR; Paradkar A
    Drug Dev Ind Pharm; 2005 Oct; 31(9):851-60. PubMed ID: 16305996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and evaluation of floating risedronate sodium Gelucire 39/01 matrices.
    Chauhan B; Shimpi S; Mahadik K; Paradkar A
    Acta Pharm; 2004 Sep; 54(3):205-14. PubMed ID: 15610617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and evaluation of diltiazem hydrochloride-Gelucire 43/01 floating granules prepared by melt granulation.
    Shimpi S; Chauhan B; Mahadik KR; Paradkar A
    AAPS PharmSciTech; 2004 Jul; 5(3):e43. PubMed ID: 15760076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroretentive extended-release floating granules prepared using a novel fluidized hot melt granulation (FHMG) technique.
    Zhai H; Jones DS; McCoy CP; Madi AM; Tian Y; Andrews GP
    Mol Pharm; 2014 Oct; 11(10):3471-83. PubMed ID: 25105340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Gelucire 43/01 beads of metformin hydrochloride for floating delivery.
    Jain SK; Gupta A
    AAPS PharmSciTech; 2009; 10(4):1128-36. PubMed ID: 19830579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of risedronate nanoparticles by solvent evaporation technique.
    Vaculikova E; Placha D; Pisarcik M; Peikertova P; Dedkova K; Devinsky F; Jampilek J
    Molecules; 2014 Nov; 19(11):17848-61. PubMed ID: 25375330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and characterization of cefuroxime axetil biphasic floating minitablets.
    Jammula S; Patra ChN; Swain S; Panigrahi KC; Nayak S; Dinda SC; Rao ME
    Drug Deliv; 2015 Jan; 22(1):125-35. PubMed ID: 24417642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Floating granules of ranitidine hydrochloride-gelucire 43/01: formulation optimization using factorial design.
    Patel DM; Patel NM; Patel VF; Bhatt DA
    AAPS PharmSciTech; 2007 Apr; 8(2):Article 30. PubMed ID: 17622108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compatibility study between ibuproxam and pharmaceutical excipients using differential scanning calorimetry, hot-stage microscopy and scanning electron microscopy.
    Mura P; Faucci MT; Manderioli A; Bramanti G; Ceccarelli L
    J Pharm Biomed Anal; 1998 Oct; 18(1-2):151-63. PubMed ID: 9863953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compatibility of risedronate sodium tablets with food thickeners.
    Dansereau RJ; Crail DJ
    Am J Health Syst Pharm; 2008 Nov; 65(22):2133-6. PubMed ID: 18997142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aging on the release of salbutamol sulfate from lipid matrices.
    San Vicente A; Hernández RM; Gascón AR; Calvo MB; Pedraz JL
    Int J Pharm; 2000 Nov; 208(1-2):13-21. PubMed ID: 11064207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different modalities of NaCl osmogen in biodegradable microspheres for bone deposition of risedronate sodium by alveolar targeting.
    Nasr M; Awad GA; Mansour S; Taha I; Al Shamy A; Mortada ND
    Eur J Pharm Biopharm; 2011 Nov; 79(3):601-11. PubMed ID: 21827854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation, characterization, release kinetics, and in vitro cytotoxicity of calcium silicate cement as a risedronate delivery system.
    Gong T; Wang Z; Zhang Y; Sun C; Yang Q; Troczynski T; Häfeli UO
    J Biomed Mater Res A; 2014 Jul; 102(7):2295-304. PubMed ID: 23946228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hot melt extruded transdermal films based on amorphous solid dispersions in Eudragit RS PO: The inclusion of hydrophilic additives to develop moisture-activated release systems.
    Albarahmieh E; Qi S; Craig DQM
    Int J Pharm; 2016 Nov; 514(1):270-281. PubMed ID: 27863672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive effect of vitamin K2 and risedronate on long bone mass in hypophysectomized young rats.
    Iwamoto J; Takeda T; Sato Y; Yeh JK
    Exp Anim; 2007 Apr; 56(2):103-10. PubMed ID: 17460355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone microdamage.
    Chapurlat RD
    Osteoporos Int; 2009 Jun; 20(6):1033-5. PubMed ID: 19340506
    [No Abstract]   [Full Text] [Related]  

  • 17. Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss.
    Kwak HB; Kim JY; Kim KJ; Choi MK; Kim JJ; Kim KM; Shin YI; Lee MS; Kim HS; Kim JW; Chun CH; Cho HJ; Hong GY; Juhng SK; Yoon KH; Park BH; Bae JM; Han JK; Oh J
    Biol Pharm Bull; 2009 Jul; 32(7):1193-8. PubMed ID: 19571384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study on mechanism for amorphous drug stabilization using gelucire 50/13.
    Shimpi SL; Mahadik KR; Paradkar AR
    Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):937-42. PubMed ID: 19721253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risedronate improves bone mineral density in Crohn's disease: a complementary mechanism.
    Namazi H
    J Crohns Colitis; 2012 Jul; 6(6):734. PubMed ID: 22483568
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats.
    Iwamoto J; Takeda T; Sato Y; Shen CL; Yeh JK
    Exp Anim; 2006 Oct; 55(5):457-66. PubMed ID: 17090962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.